📢 Pharmasaga Global Expansion: Awarded the MoEA TREE Grant to Accelerate Global Licensing & Fundraising!

🔗Link

A monumental milestone for Pharmasaga (7878.TW) as we advance into the global diabetes treatment market! We are thrilled to announce that we have officially received the prestigious TREE Program subsidy grant from the Department of Industrial Technology, MoEA.

Guided by the Industrial Technology Research Institute (ITRI), the Pharmasaga team has traveled the U.S. to integrate with the global biotech ecosystem. Our strategic objectives for this tour are clear and high-impact:
Connecting at SelectUSA Summit: Engaging directly with the U.S. Department of Commerce and state-level resources to secure optimal sites and strategic collaborations for our flagship drug, PS1 (PDIA4 inhibitor), in upcoming U.S. clinical trials.

Accelerating at UC Berkeley Skydeck: Leveraging the elite mentorship of Berkeley's top accelerating program to optimize our global commercial model.
Expanding International Licensing: While deepening ongoing strategic discussions with our existing pharmaceutical partners, we are actively establishing connections with new global pharma giants to negotiate global licensing and diversified fundraising opportunities.

Our Core Commitment: Endogenous Repair ╳ AI Compute Centered around our proprietary PS1 platform, we focus on repairing the body's native insulin factories rather than relying on external supplements. By integrating advanced AI compute to supercharge R&D efficiency, we are bringing a scientific breakthrough to the international stage: "Cell Death Rate < Regeneration Rate = Reversing Disease Progression."

Backed by robust empirical data and agile business logic, Pharmasaga is moving full speed ahead in Silicon Valley! We welcome potential global partners and investors to connect with us to explore future collaborative horizons.🚀